MedTrace Logo

Risk Stratification Using PET in HCM

NCT03278457 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2017-09-11

No results posted yet for this study

Summary

The overall rationale is to reduce the risk of sudden cardiac death in individuals with hypertrophic cardiomyopathy (HCM). The novel approach of this study is to correlate Positron Emission Tomography (PET) findings to ventricular arrhythmias detected by the implantable cardioverter defibrillator (ICD). This could potentially lead to an improved risk stratification of HCM patients.

Conditions

Interventions

DIAGNOSTIC_TEST

Positron Emission Tomography

Positron Emission Tomography

Sponsors & Collaborators

  • Landstinget i Värmland

    collaborator OTHER

  • Dalarna County Council, Sweden

    collaborator OTHER

  • Uppsala University Hospital

    collaborator OTHER

  • Region Gävleborg

    lead OTHER

Principal Investigators

  • Jens Sörensen, MD PhD · Region Gävleborg

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-03
Primary Completion
2018-01-03
Completion
2018-06-03

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03278457 on ClinicalTrials.gov